Showing 4471-4480 of 5556 results for "".
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Colloidal Oatmeal Cream Soothes AD in Black Childrenhttps://practicaldermatology.com/news/colloidal-oatmeal-cream-soothes-ad-in-black-children/2462018/Oatmeal cream may help ease atopic dermatitis in Black children, according to research presented at the Science of Skincare Summit in Austin, Texas. Black children are 1.7 times more likely to dev
- UCB Anticipates Delay for FDA Bimekizumab Decisionhttps://practicaldermatology.com/news/ucb-anticipates-delay-for-fda-bimekizumab-decision/2462017/The anticipated Biologics License Application (BLA) for bimekizumab to treat plaque psoriasis will likely be delayed beyond Q3 2023, according to a statement from UCB. Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) an
- Beyond BSA: IPC, NPF Call Attention to Psoriasis Lesion Location on Q of Lhttps://practicaldermatology.com/news/beyond-bsa-ipc-npf-call-attention-to-psoriasis-lesion-location-on-q-of-l/2462007/The International Psoriasis Council (IPC) is partnering with the National Psoriasis Foundation (NPF) to call attention to the influence of psoriasis lesion locations on patients’ quality of life. The joint effort presents a study that delves into how psoriasis in specific areas
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- TikTok Trend Watch: Is Beer Tanning Really a Thing?https://practicaldermatology.com/news/tik-tok-trend-watch-is-beer-tanning-really-a-thing/2461976/TikTok is where many trends and DIY challenges get started, and skincare is one of the more popular categories for this content, for better or sometimes for worse. Take beer tanning, for example. Tik Tokkers are claiming that pouring beer on skin will activate melanin for a better
- Kenvue Launches Two New Tylenol Precise Pain-relieving Creamshttps://practicaldermatology.com/news/kenvue-launches-two-new-tylenol-precise-pain-relieving-creams/2461973/Kenvue Inc. is rolling out two new topical pain-relieving creams: Tylenol Precise Pain Relieving Cream and Tylenol Precise Cooling Pain Relieving Cream. These are among the first U.S. product launches from Kenvue since it became a publicly traded
- Are Wealthy People at Higher Risk for Skin Cancer?https://practicaldermatology.com/news/are-wealthy-people-are-more-prone-to-skin-cancer/2461972/Wealthier people are at greater risk for melanoma, according to new research in Cancers. “A higher socio-economic status is known to be associated with more vacations in sunny climates and recreational tanning, which likely ultimately drives melanoma incidence in this pop